fcγr

BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Ofatumumab is a humanized monoclonal antibody targeting CD20. Ofatumumab acts on CD20-expressing B lymphocytes, inducing antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO cells, targeting Fc gamma R1. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

The Anti-CD32/FcγRIIA Antibody (IV.3) is a chimeric mouse IgG2b antibody designed to target human CD32/FcγRIIA. The recommended isotype control for this antibody is Mouse IgG2b kappa, Isotype Control.

(±)-Haloxyfop (Haloxyfop Acid) is a herbicide.

hIgG-hFc receptor-IN-1 is a human immunoglobulin G - human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction inhibitor (IC50: 2 μM).

F-CRI1, a potent STING agonist with a dissociation constant (K d) of 40.62 nM, is an 18F-labeled radioactive probe employed for visualizing STING in the tumor microenvironment [1].

Transferrin aldifitox (TF-CRM107), a conjugate of diphtheria toxin CRM107 with transferrin, can be used for anticancer research [1].

Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an IgG1 antibody inhibitor derived from mice, specifically targeting rat FcRn heavy chain heterodimers.

Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is a mouse-derived antibody, specifically targeting the FcRn heavy chain heterodimers. The isotype control for Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is designated as MouseIgG1kappa, Isotype Control.

Rilzabrutinib (PRN1008) is a reversible covalent, selective, and orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an IC50 of 1.3 nM.

BTK-IN-11 is a potent BTK inhibitor with potential applications in research on autoimmune diseases, inflammatory diseases, and cancer.

Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed as a decoy or scavenger to target Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating autoimmune diseases, with a particular focus on systemic lupus erythematosus (SLE) research [1].

PKC-ε Translocation Inhibitor Peptide is a selective modulator that controls the FcγR-mediated internalization rate of opsonized beads without affecting FcαR trafficking [1].

BI-1808 is a human IgG1 monoclonal antibody targeting TNFR2. It blocks the interaction between TNFR2 and its ligand TNF-α, leading to FcγR-dependent regulatory T cell depletion and facilitating the expansion of intratumoral CD8+ T cells.